Quotes 5-day view Delayed Nasdaq
01/14/2021
01/15/2021
01/19/2021
01/20/2021
01/21/2021
Date
20.67(c)
20.83(c)
21.69(c)
20.99(c)
20.93 Last
1 214 629
837 138
1 407 346
840 399
390 320 Volume
+5.89% +0.77% +4.13% -3.23% -0.29% Change
Sales 2020
32,8 M - -
Net income 2020
-108 M - -
Net Debt 2020
-
-
-
P/E ratio 2020
-7,43x
Yield 2020
-
Sales 2021
15,3 M - -
Net income 2021
-164 M - -
Net Debt 2021
-
-
-
P/E ratio 2021
-5,37x
Yield 2021
-
Capitalization
799 M 799 M -
Capi. / Sales 2020
24,3x
Capi. / Sales 2021
52,2x
Nbr of Employees
104
Free-Float
88,8%
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It...
Notations Surperformance© of G1 Therapeutics, Inc.
Trading Rating : Investor Rating : -
All news about G1 THERAPEUTICS, INC.
News in other languages on G1 THERAPEUTICS, INC.
- No features available -
Chart G1 THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends G1 THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
8
Average target price
50,00 $
Last Close Price
20,99 $
Spread / Highest target
291%
Spread / Average Target
138%
Spread / Lowest Target
0,05%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
